News Conference News ACC 2020 VOYAGER PAD: Rivaroxaban Bests Aspirin Alone for Preventing Limb and CV Events L.A. McKeown March 28, 2020
News Features Mixed Messages on COVID-19 Masks: Science Falls Short As Deaths Mount Shelley Wood March 27, 2020
News Daily News ACE Inhibitors, ARBs, and COVID-19: New Insights, Advice Yael L. Maxwell March 26, 2020
News Daily News Cardiac Injury in COVID-19 Sharply Increases Risk of Death Caitlin E. Cox March 26, 2020
News Daily News Center Site, Volume Affect Uptake of Same-Day Discharge for Elective PCI L.A. McKeown March 18, 2020
News Opinion Editor's Corner COVID-19 and the Heart: Insights From the Front Lines Shelley Wood March 12, 2020
News Daily News LEADER Analysis Reassures on Liraglutide in Diabetic Patients With Heart Failure Shelley Wood March 10, 2020
News Daily News One Egg a Day? No Link to Risk of CVD, Mega-Meta-analysis Says Michael O'Riordan March 06, 2020
News Daily News Habitual Use of Fish Oil Prevents CVD, Real-world Data Suggest Todd Neale March 05, 2020
News Daily News Meta-analysis Questions PCI vs CABG in Women With Multivessel Disease Shelley Wood February 27, 2020
News Conference News ISC 2020 Telehealth Program Helps Minority Stroke Survivors Control BP Todd Neale February 26, 2020
News Conference News ISC 2020 Antihypertensive Treatment is Subpar After ICH Todd Neale February 19, 2020
News Daily News ACC Releases Initial Cardiac Guidance on Novel Coronavirus Todd Neale February 13, 2020
News Daily News Trials of New Cancer Drugs Failing to Address Potential CV Risks Todd Neale February 10, 2020
News Opinion Editor's Corner TCTMD’s Top 10 Most Popular Stories for January 2020 Shelley Wood January 31, 2020
News Daily News Revascularization After PCI or CABG Linked to Higher Mortality: EXCEL Michael O'Riordan January 17, 2020
News Daily News Pricey, Unproven ‘Executive’ CVD Screening the Norm at Top US Hospitals Michael O'Riordan January 16, 2020
News Daily News Lp(a) Reduction Contributes to Alirocumab’s Treatment Benefit: ODYSSEY Outcomes Michael O'Riordan January 14, 2020
News Features ‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry Michael O'Riordan January 10, 2020